This Week: Lusaris Raises $60m to Develop 5-MeO-DMT Turnbull’s Nonprofit Turns For-profit? COMPASS Phase 2b Published in NEJM Apex Labs Gets Go-Ahead for Take-home Psilocybin Trial and lots more… Lusaris Raises $60m to Develop 5-MeO-DMT GH Research’s lead investor incubates its own 5-MeO-DMT company: Lusaris Therapeutics has emerged from stealth with a $60m Series A round, led by RA Capital…


Previous articleCOMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
Next articleWebinar – The Dark Side of Psychedelic Therapies